Is Torrent Pharmaceuticals (TORNTPHARM) overvalued or fairly valued?

MarketChacha shows Torrent Pharmaceuticals's valuation in context — a forward P/E of about 52.7, a price-to-book of about 19.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Torrent Pharmaceuticals's revenue?

Torrent Pharmaceuticals reported revenue of ₹10,712 Cr for FY2026, with net profit of ₹2,192 Cr, per official filings.

What is the share price of Torrent Pharmaceuticals (TORNTPHARM)?

Torrent Pharmaceuticals last traded at ₹4,857.00 (-3.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Torrent Pharmaceuticals

TORNTPHARM · NSE · Pharma · India

Snapshot

TickerTORNTPHARM

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees18,258

HeadquartersAhmedabad, India

Websitewww.torrentpharma.com

Filings tracked3

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Who owns it

Promoters63.4%
Institutions19.4%
Public & other17.2%

243 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.9% → 15.5%

Margin has expanded by about 2.5 points — the business is getting more profitable.

Growth qualityrev 10% · PAT 15%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,950 Cr · EPS 16.95

Est. earnings growth -10.8%

Next fiscal year

Rev ₹22,282 Cr · EPS 93.15

Est. earnings growth +38.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹13,980 Cr

Net margin

15.5%

Revenue CAGR (3y)

+13.3%

Profit CAGR (3y)

+20.2%

Net profit (FY2026)

₹2,163 Cr

Ask MarketChacha about TORNTPHARM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹13,980 Cr	₹2,163 Cr	15.5%
FY2025	₹11,516 Cr	₹1,911 Cr	16.6%
FY2024	₹10,728 Cr	₹1,656 Cr	15.4%
FY2023	₹9,620 Cr	₹1,245 Cr	12.9%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹4,921 Cr	₹566 Cr	11.5%
Q4 FY26	₹4,197 Cr	₹389 Cr	9.3%
Q3 FY26	₹3,303 Cr	₹635 Cr	19.2%
Q2 FY26	₹3,302 Cr	₹591 Cr	17.9%
Q1 FY26	₹3,178 Cr	₹548 Cr	17.2%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating
ESG Rating
BSE8/11/2026
Change in Management
Appointment of Shanti Ekambaram as an Independent Director of the Company
BSE7/28/2026
Receipt Of Final Listing And Trading Approval For Equity Shares Of The Company Issued And Allotted In Terms Of Scheme Of Amalgamation
Receipt of final listing and Trading approval for Equity shares of the Company issued and allotted in terms of Scheme of Amalgamation
BSE7/27/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.